Search Results - "Zannad, Faiez"

Rising incidence of heart failure demands action by Zannad, Faiez

“…Heart failure is a life-threatening syndrome with substantial morbidity and mortality and is a burden to patients, their carers, and health systems. Estimates…”
Get full text

Cardiorenal Syndrome Revisited by Zannad, Faiez, Rossignol, Patrick

“…Cardiorenal syndromes have been categorized into 5 clinical subtypes based on which organ is perceived to be the primary precipitant of the vicious and…”
Get full text

SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat by Girerd, Nicolas, Zannad, Faiez

“…Sodium–glucose transport inhibitors (SGLT2i) are effective in heart failure (HF) with ejection fraction (EF) <40% (referred to as HF with reduced EF – HFrEF)…”
Get full text

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine by Agarwal, Rajiv, Kolkhof, Peter, Bakris, George, Bauersachs, Johann, Haller, Hermann, Wada, Takashi, Zannad, Faiez

“…Abstract This review covers the last 80 years of remarkable progress in the development of mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of…”
Get full text

Heart failure drug treatment by Rossignol, Patrick, Hernandez, Adrian F, Solomon, Scott D, Zannad, Faiez

“…Heart failure is the most common cardiovascular reason for hospital admission for people older than 60 years of age. Few areas in medicine have progressed as…”
Get full text

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials by Zannad, Faiez, Ferreira, João Pedro, Pocock, Stuart J, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Brueckmann, Martina, Ofstad, Anne Pernille, Pfarr, Egon, Jamal, Waheed, Packer, Milton

“…Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition…”
Get full text

Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment by Boorsma, Eva M., ter Maaten, Jozine M., Damman, Kevin, Dinh, Wilfried, Gustafsson, Finn, Goldsmith, Steven, Burkhoff, Daniel, Zannad, Faiez, Udelson, James E., Voors, Adriaan A.

“…Congestion is the main reason for hospitalization in patients with acute decompensated heart failure and is an important target for therapy. However, achieving…”
Get full text

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials by Vaduganathan, Muthiah, Claggett, Brian L, Jhund, Pardeep S, Cunningham, Jonathan W, Pedro Ferreira, João, Zannad, Faiez, Packer, Milton, Fonarow, Gregg C, McMurray, John J V, Solomon, Scott D

“…Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin receptor–neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2…”
Get full text

Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials by Packer, Milton, Zannad, Faiez, Anker, Stefan D.

Get full text

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure by Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R, Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez

“…Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of…”
Get full text

Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure by Cowie, Martin R, Woehrle, Holger, Wegscheider, Karl, Angermann, Christiane, d’Ortho, Marie-Pia, Erdmann, Erland, Levy, Patrick, Simonds, Anita K, Somers, Virend K, Zannad, Faiez, Teschler, Helmut

“…Patients with heart failure and sleep apnea were assigned to adaptive servo-ventilation or control. The rate of death, lifesaving cardiovascular intervention,…”
Get full text

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure by Ferreira, João Pedro, Zannad, Faiez, Pocock, Stuart J., Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Brueckmann, Martina, Jamal, Waheed, Steubl, Dominik, Schueler, Elke, Packer, Milton

“…Mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 inhibitors favorably influence the clinical course of patients with heart…”
Get full text

Empagliflozin and Major Renal Outcomes in Heart Failure by Packer, Milton, Butler, Javed, Zannad, Faiez, Pocock, Stuart J, Filippatos, Gerasimos, Ferreira, João P, Brueckmann, Martina, Jamal, Waheed, Zeller, Cordula, Wanner, Christoph, Anker, Stefan D

“…In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2.8% of the…”
Get full text

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease by Zannad, Faiez, Anker, Stefan D, Byra, William M, Cleland, John G.F, Fu, Min, Gheorghiade, Mihai, Lam, Carolyn S.P, Mehra, Mandeep R, Neaton, James D, Nessel, Christopher C, Spiro, Theodore E, van Veldhuisen, Dirk J, Greenberg, Barry

“…Patients with heart failure, coronary artery disease, and no atrial fibrillation were randomly assigned to receive 2.5 mg of rivaroxaban twice daily or…”
Get full text

Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure by Coiro, Stefano, Rossignol, Patrick, Ambrosio, Giuseppe, Carluccio, Erberto, Alunni, Gianfranco, Murrone, Adriano, Tritto, Isabella, Zannad, Faiez, Girerd, Nicolas

“…Aims Residual pulmonary congestion at discharge is associated with poor prognosis in heart failure (HF), but its quantification through physical examination is…”
Get full text

The evolving landscape of pulmonary arterial hypertension clinical trials by Weatherald, Jason, Boucly, Athénaïs, Peters, Anthony, Montani, David, Prasad, Krishna, Psotka, Mitchell A, Zannad, Faiez, Gomberg-Maitland, Mardi, McLaughlin, Vallerie, Simonneau, Gérald, Humbert, Marc

“…Although it is a rare disease, the number of available therapeutic options for treating pulmonary arterial hypertension has increased since the late 1990s,…”
Get full text

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction by Tromp, Jasper, Westenbrink, B. Daan, Ouwerkerk, Wouter, van Veldhuisen, Dirk J., Samani, Nilesh J., Ponikowski, Piotr, Metra, Marco, Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, van der Harst, Pim, Lang, Chim C., Ng, Leong L., Zannad, Faiez, Zwinderman, Aelko H., Hillege, Hans L., van der Meer, Peter, Voors, Adriaan A.

“…Information on the pathophysiological differences between heart failure with reduced ejection fraction (HFrEF) versus heart failure with preserved ejection…”
Get full text

Head-to-head comparison of clustering methods for heterogeneous data: a simulation-driven benchmark by Preud’homme, Gregoire, Duarte, Kevin, Dalleau, Kevin, Lacomblez, Claire, Bresso, Emmanuel, Smaïl-Tabbone, Malika, Couceiro, Miguel, Devignes, Marie-Dominique, Kobayashi, Masatake, Huttin, Olivier, Ferreira, João Pedro, Zannad, Faiez, Rossignol, Patrick, Girerd, Nicolas

“…The choice of the most appropriate unsupervised machine-learning method for “heterogeneous” or “mixed” data, i.e. with both continuous and categorical…”
Get full text

Abnormalities of Potassium in Heart Failure by Ferreira, João Pedro, Butler, Javed, Rossignol, Patrick, Pitt, Bertram, Anker, Stefan D., Kosiborod, Mikhail, Lund, Lars H., Bakris, George L., Weir, Matthew R., Zannad, Faiez

“…Potassium (K+) is the most abundant cation in humans and is essential for normal cellular function. Alterations in K+ regulation can lead to neuromuscular,…”
Get full text

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial by Zannad, Faiez, Prof, Cannon, Christopher P, Prof, Cushman, William C, Prof, Bakris, George L, Prof, Menon, Venu, MD, Perez, Alfonso T, MD, Fleck, Penny R, MBA, Mehta, Cyrus R, PhD, Kupfer, Stuart, MD, Wilson, Craig, PhD, Lam, Hung, PhD, White, William B, Prof

“…Summary Background The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in…”
Get full text